Open AccessDimeditiapramine (Ro 11‐1781), a new calcium antagonist, in the management of supraventricular tachyarrhythmias in patients with acute myocardial infarction
Author(s) -
Cocco G.,
Chu D.,
Strozzi C.
Publication year - 1979
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960020208
Subject(s) - medicine , asystole , atrial flutter , cardiology , myocardial infarction , atrial fibrillation , supraventricular tachycardia , supraventricular arrhythmia , anesthesia , tachycardia , blood pressure , antiarrhythmic agent , heart rate , antagonist , fibrillation , heart disease , receptor
18 patients with acute myocardial infarction and sustained arrhythmias were treated with a new Ca 2+ antagonist, Ro 11‐1781, at the dose of 1.0 mg/kg i.v. The drug was effective in reducing heart rate to less than 90 beats/min in 9/10 patients with atrial fibrillation, in 3/4 patients with atrial flutter and in 3/4 patients with supraventricular tachycardia. The peak effect was observed within 2‐5 min after the intravenous administration of Ro 11‐1781. In cases with recurring tachyarrhythmias, the drug was also effective in repetitive administration. Systolic blood pressure was reduced, but severe hypotension (< 90 mm Hg) was not observed. The atrioventricular conduction in these patients remained unimpaired and asystole did not occur. The drug appears to be an effective and a well tolerated antiarrhythmic agent.